OncoMatch/Clinical Trials/NCT04136782

Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer

Is NCT04136782 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies multiple treatments including Albumin-bound paclitaxel combined with carboplatin and Epirubicin combined with docetaxel for breast cancer.

Phase 4RecruitingShengjing HospitalNCT04136782Data as of May 2026

Treatment: Albumin-bound paclitaxel combined with carboplatin · Epirubicin combined with docetaxel — To investigate the efficacy of albumin-bound paclitaxel combined with carboplatin versus epirubicin combined with docetaxel as neoadjuvant therapy for triple-negative breast cancer.

Check if I qualify

Extracted eligibility criteria

Cancer type

Breast Carcinoma

Biomarker criteria

Required: HER2 (ERBB2) negative (negative)

Required: ESR1 negative (negative)

Required: PR (PGR) negative (negative)

Disease stage

Required: Stage II, III

Excluded: Stage IV

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: antineoplastic therapy

those who have received antineoplastic therapy

Cannot have received: neoadjuvant chemotherapy

Exception: patients who fail in 2 cycles of neoadjuvant chemotherapy and switch to other regimens or terminate chemotherapy

those who have received neoadjuvant chemotherapy but fail in 2 cycles of neoadjuvant chemotherapy and switch to other regimens or terminate chemotherapy

Lab requirements

Blood counts

normal routine blood test results

Kidney function

normal kidney function

Liver function

normal liver function

Cardiac function

near normal electrocardiographic manifestations

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify